The growth of private equity investment in health care is facing sharp scrutiny from investors, regulators, and the public. Some view private equity as a key to transforming the U.S. health system. Others raise concerns that profits for corporate investors will be at the expense of patients’ health, workers’ safety, and affordability. LDI Senior Fellows Mark V. Pauly and Lawton Robert Burns argue that we have seen this movie before. Looking at past private equity purchases will help us understand the future.
In their study, published in the Journal of Health Politics, Policy, and Law, they identify two historical waves of private equity investment in physician practices—in the 1990s and from the passage of the Affordable Care Act in 2010 to the present. They then assess the similarities between the investment goals of each wave—shown in the table above. Pauly and Burns say that strategies across private equity investment have largely stayed consistent. However, the investigators say there’s “less public information on firm performance” today. So, they argue, the current “brouhaha” should be tempered by past experience.
The study, “Equity Investment in Physician Practices: What’s All This Brouhaha?,” was published on February 7, 2024 in the Journal of Health Politics, Policy, and Law. Authors include Mark V. Pauly and Lawton Robert Burns.
Author
More on Health Care Access & Coverage
Cost and Convenience Drive PrEP Use for Transgender People
Survey Reveals How to Shape PreP Care for the Future
Adding Diversity to Your Research Process: A New System
Penn Team Creates Guidelines and Best Practices Overview
Do Wealth and Poverty Affect Access to Less-Invasive Cardiac Surgery?
Advanced Care Is Less Common in Neighborhoods with Higher Deprivation, LDI Fellows Find
A Big Boost for Patients That Largely Went Away: Telemedicine Made Care More Available During the Pandemic
Now It’s in Retreat. One Idea Is to Create a Federal License to Practice
This Doctor Spends Hours Talking to Insurers. Her Patients Suffer The Most.
Prior Authorizations Were Meant to Cut Costs. Now They Delay Care, Says CHOP Rheumatologist
FDA Boosted Florida’s Drug Import Plan From Canada, But the Canadians and Big Pharma Probably Won’t Play Along
There Are Better Ways to Achieve These Goals, an LDI Expert Writes